webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N3-L-Cys(Trt)-OH CHA

  CAS No.: 1286670-90-3   Cat No.: BADC-01723   Purity: >98% 4.5  

N3-L-Cys(Trt)-OH (CHA) is a cysteine-based azide ADC linker intermediate with Trt protection, designed for click chemistry conjugation in antibody-drug conjugates. It enables controlled payload release and improved linker stability. Keywords: ADC linker, cysteine linker, azide functional group, click chemistry, cleavable linker.

N3-L-Cys(Trt)-OH CHA

Structure of 1286670-90-3

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C28H32N4O2S
Molecular Weight
488.65
Shipping
Store at 2-8 °C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
S-Trityl-L-azidocysteine CHA salt; N3-Cys(Trt)-OH.CHA; azido-Cys(Trt).CHA; alpha-Azido-S-trityl cysteine cyclohexylamine salt; (R)-2-Azido-3-(tritylthio)propanoic acid cyclohexylammonium salt; N3-Cys(Trt).CHA; Propanoic acid, 2-azido-3-[(triphenylmethyl)thio]-, compd. with cyclohexanamine (1:1), (2R)-; Cyclohexanaminium (R)-2-azido-3-(tritylthio)propanoate; N3-Cys(Trt)-OH CHA salt
IUPAC Name
(2R)-2-azido-3-tritylsulfanylpropanoic acid;cyclohexanamine
Canonical SMILES
C1CCC(CC1)N.C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)SC[C@@H](C(=O)O)N=[N+]=[N-]
InChI
InChI=1S/C22H19N3O2S.C6H13N/c23-25-24-20(21(26)27)16-28-22(17-10-4-1-5-11-17,18-12-6-2-7-13-18)19-14-8-3-9-15-19;7-6-4-2-1-3-5-6/h1-15,20H,16H2,(H,26,27);6H,1-5,7H2/t20-;/m0./s1
InChIKey
WMAKHHJCDUBSCM-BDQAORGHSA-N
Storage
Store at 2-8 °C

N3-L-Cys(Trt)-OH (CHA) is a critical reagent in peptide synthesis, used to incorporate cysteine residues into peptides with enhanced stability and reactivity. The Trt (trityl) protection group on the cysteine thiol group is essential for controlling reactivity during solid-phase peptide synthesis (SPPS), as it prevents unwanted side reactions while still allowing for efficient peptide elongation. The N3-protection ensures that the cysteine residue can be introduced into peptide sequences without compromising the synthesis process, making it a versatile tool in peptide chemistry.

One of the key applications of N3-L-Cys(Trt)-OH (CHA) is in the creation of peptides with disulfide bonds. Cysteine residues are essential for forming these bonds, which are critical for stabilizing the three-dimensional structure of many bioactive peptides. The controlled introduction of cysteine using N3-L-Cys(Trt)-OH allows for the synthesis of cyclic peptides, which are more resistant to proteolysis and often have higher binding affinity for their target proteins. These cyclic peptides are used extensively in drug discovery, particularly for targeting protein-protein interactions and enzyme inhibition.

N3-L-Cys(Trt)-OH (CHA) is also employed in the synthesis of peptide-drug conjugates (PDCs), where cysteine is often used to link peptides with therapeutic agents such as cytotoxic drugs or targeting molecules. The thiol group on cysteine can undergo selective conjugation with various compounds, enabling the development of highly targeted therapies. This approach is particularly useful in oncology, where PDCs can deliver potent drugs directly to tumor cells, minimizing off-target effects and improving therapeutic efficacy.

Another significant application of N3-L-Cys(Trt)-OH (CHA) is in the development of peptides for biomedical and diagnostic applications. The thiol group of cysteine can be used for conjugating peptides to various diagnostic markers or imaging agents, allowing for targeted imaging in disease diagnosis. This is especially relevant in the development of molecular imaging probes for cancer, cardiovascular diseases, and neurodegenerative disorders. The controlled reactivity of the cysteine residue, protected by the Trt group, ensures that the conjugation process is precise and efficient.

Lastly, N3-L-Cys(Trt)-OH (CHA) is essential in the design of peptide-based vaccines and therapeutic peptides for immune modulation. Cysteine residues play an important role in protein structure and function, and their inclusion in vaccine peptides can help stabilize the vaccine’s conformation, ensuring a stronger and longer-lasting immune response. By incorporating N3-L-Cys(Trt)-OH, researchers can create peptides that are better suited for immune system activation and more effective as vaccines against infections, cancer, or autoimmune diseases.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Daunorubicin citrate | N3-L-Val-OH (CHA) | N3-L-Cys(Trt)-OH CHA
Send Inquiry
Verification code
Inquiry Basket